{"id":"olanzapine-samidorphan-exercise","safety":{"commonSideEffects":[{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Metabolic dysfunction"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine acts as a dopamine and serotonin antagonist to manage psychotic symptoms, but commonly causes weight gain and metabolic dysfunction. Samidorphan is a mu-opioid receptor antagonist that blocks opioid-mediated appetite stimulation and metabolic effects, reducing olanzapine-induced weight gain. Exercise serves as an additional non-pharmacological intervention to further improve metabolic outcomes and overall health.","oneSentence":"Olanzapine-samidorphan combines an atypical antipsychotic (olanzapine) with a mu-opioid receptor antagonist (samidorphan) to treat schizophrenia and bipolar disorder while mitigating weight gain, with exercise as a behavioral intervention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:03.490Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder"}]},"trialDetails":[{"nctId":"NCT06740890","phase":"PHASE4","title":"Exercise and Olanzapine-samidorphan","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2025-06-26","conditions":"Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Olanzapine-samidorphan + exercise","genericName":"Olanzapine-samidorphan + exercise","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine-samidorphan is a serotonin 2a (5-HT2a) receptor antagonist used to treat conditions such as schizophrenia, schizoaffective disorder, bipolar disorder I or II, and bipolar disorder NOS. When combined with exercise, it is being studied as a potential treatment in a proof of concept study (NCT06740890) for the prevention of early weight gain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}